# Tasca Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/tasca-therapeutics

- Industry: Biotechnology
- Headquarters: Boston, US
- Website: www.tascatx.com
- Total disclosed funding: $76M
- Latest round: Series A (Dec 10, 2024)
- Investors on record: 3

## About

Based in Massachusetts, US, and founded in 2021, Tasca Therapeutics, Inc. operates as a biotechnology company. The company was founded by its CEO, Milenko Cicmil, Xu Wu, David Fisher, and Duojua Pan. In December 2024, Tasca Therapeutics, Inc. raised USD 52 million in Series A funding co-led by Regeneron Ventures, Cure Ventures, and Invus.

Tasca Therapeutics specializes in developing innovative small-molecule inhibitors aimed at treating various oncology indications. The company's core product offerings stem from a drug discovery platform that identifies and maps novel lipid-binding pockets on proteins, which enables the creation of targeted therapies designed to improve treatment outcomes for cancer patients. The end users of these products include healthcare providers and oncologists who prescribe treatments to patients battling cancer.

The revenue model for the company involves partnerships with research institutions and pharmaceutical industry collaborators, facilitating the development and commercialization of its proprietary therapies.

The company plans to utilize the funding raised in December 2024 to advance its drug discovery platform, progress its lead program CP-383 into Phase 1/2 clinical studies, and expand its drug pipeline.

## Funding rounds

- Series A, Dec 10, 2024, $52M — Invus [DUP], Cure Ventures, Regeneron Ventures
- Series A, Nov 13, 2024, $24M — Invus [DUP], Cure Ventures, Regeneron Ventures

## Investors

- Invus [DUP] — Series A
- Cure Ventures (https://capitalatlas.ai/funds/cure-ventures) — Series A
- Regeneron Ventures (https://capitalatlas.ai/funds/regeneron-ventures) — Series A